Alpa Laboratories Limited (ALPA.BO)
INR 105.3
(3.34%)
INR 105.3
(3.34%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.08 Billion INR | 17.67% |
| 2022 | 924.1 Million INR | -16.38% |
| 2021 | 1.1 Billion INR | 14.62% |
| 2020 | 964.13 Million INR | 13.6% |
| 2019 | 848.7 Million INR | 11.06% |
| 2018 | 764.21 Million INR | 23.46% |
| 2017 | 618.97 Million INR | -1.03% |
| 2016 | 625.42 Million INR | 16.7% |
| 2015 | 535.9 Million INR | -6.63% |
| 2014 | 573.93 Million INR | 1.21% |
| 2013 | 567.08 Million INR | 1.07% |
| 2012 | 561.09 Million INR | 1.78% |
| 2011 | 551.29 Million INR | -33.47% |
| 2010 | 828.67 Million INR | -11.31% |
| 2009 | 934.36 Million INR | -23.21% |
| 2008 | 1.21 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 214.43 Million INR | -9.16% |
| 2023 Q4 | 236.06 Million INR | -13.56% |
| 2023 Q1 | 254.29 Million INR | -12.71% |
| 2023 Q2 | 323.94 Million INR | 27.39% |
| 2023 Q3 | 273.08 Million INR | -15.7% |
| 2023 FY | 1.08 Billion INR | 17.67% |
| 2022 Q2 | 135.44 Million INR | -39.58% |
| 2022 FY | 924.1 Million INR | -16.38% |
| 2022 Q4 | 291.32 Million INR | 6.66% |
| 2022 Q3 | 273.13 Million INR | 101.65% |
| 2022 Q1 | 224.19 Million INR | -4.23% |
| 2021 Q3 | 293.28 Million INR | 11.71% |
| 2021 Q4 | 234.1 Million INR | -20.18% |
| 2021 Q2 | 262.55 Million INR | -16.7% |
| 2021 Q1 | 315.19 Million INR | 32.17% |
| 2021 FY | 1.1 Billion INR | 14.62% |
| 2020 Q2 | 235.12 Million INR | 44.3% |
| 2020 Q4 | 238.46 Million INR | -28.09% |
| 2020 Q1 | 162.94 Million INR | -4.51% |
| 2020 FY | 964.13 Million INR | 13.6% |
| 2020 Q3 | 331.64 Million INR | 41.05% |
| 2019 Q3 | 241.26 Million INR | 2.61% |
| 2019 FY | 848.7 Million INR | 11.06% |
| 2019 Q1 | 201.67 Million INR | 15.06% |
| 2019 Q2 | 235.12 Million INR | 16.59% |
| 2019 Q4 | 170.64 Million INR | -29.27% |
| 2018 Q3 | 259.6 Million INR | 63.19% |
| 2018 Q1 | 164.58 Million INR | 0.0% |
| 2018 FY | 764.21 Million INR | 23.46% |
| 2018 Q4 | 175.28 Million INR | -32.48% |
| 2018 Q2 | 159.07 Million INR | -3.34% |
| 2017 FY | 618.97 Million INR | -1.03% |
| 2016 FY | 625.42 Million INR | 16.7% |
| 2015 FY | 535.9 Million INR | -6.63% |
| 2015 Q2 | 125.28 Million INR | 51.61% |
| 2015 Q1 | 82.63 Million INR | -43.09% |
| 2014 Q1 | 100.64 Million INR | -45.47% |
| 2014 Q2 | 189.94 Million INR | 88.74% |
| 2014 Q3 | 138.15 Million INR | -27.27% |
| 2014 Q4 | 145.19 Million INR | 5.09% |
| 2014 FY | 573.93 Million INR | 1.21% |
| 2013 FY | 567.08 Million INR | 1.07% |
| 2013 Q2 | 137.29 Million INR | 39.34% |
| 2013 Q3 | 146.5 Million INR | 6.71% |
| 2013 Q4 | 184.55 Million INR | 25.97% |
| 2013 Q1 | 98.52 Million INR | -48.3% |
| 2012 Q3 | 120.18 Million INR | 0.76% |
| 2012 Q2 | 119.27 Million INR | -9.77% |
| 2012 Q1 | 132.18 Million INR | -9.91% |
| 2012 FY | 561.09 Million INR | 1.78% |
| 2012 Q4 | 190.58 Million INR | 58.58% |
| 2011 Q3 | 178.6 Million INR | 0.0% |
| 2011 Q4 | 146.73 Million INR | -17.84% |
| 2011 FY | 551.29 Million INR | -33.47% |
| 2010 FY | 828.67 Million INR | -11.31% |
| 2009 FY | 934.36 Million INR | -23.21% |
| 2008 FY | 1.21 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 99.776% |
| NATCO Pharma Limited | 40.02 Billion INR | 97.283% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 89.657% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | 58.055% |
| Achyut Healthcare Limited | 61.36 Million INR | -1671.888% |
| Ajanta Pharma Limited | 42.08 Billion INR | 97.416% |
| Alkem Laboratories Limited | 126.67 Billion INR | 99.142% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 98.221% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 91.607% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 99.621% |
| Bajaj HealthCare Limited | 4.73 Billion INR | 77.031% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 85.883% |
| Brooks Laboratories Limited | 794.86 Million INR | -36.803% |
| Divi's Laboratories Limited | 78.45 Billion INR | 98.614% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 99.61% |
| Eris Lifesciences Limited | 20.09 Billion INR | 94.588% |
| FDC Limited | 19.42 Billion INR | 94.403% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 99.08% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 95.237% |
| Granules India Limited | 45.06 Billion INR | 97.587% |
| Gufic Biosciences Limited | 8.06 Billion INR | 86.52% |
| Hester Biosciences Limited | 3.04 Billion INR | 64.295% |
| Indoco Remedies Limited | 17.89 Billion INR | 93.923% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 91.511% |
| Ipca Laboratories Limited | 76.22 Billion INR | 98.573% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | 47.897% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -115.66% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -4.221% |
| Laurus Labs Limited | 50.01 Billion INR | 97.826% |
| Lupin Limited | 200.1 Billion INR | 99.457% |
| Mankind Pharma Limited | 103.34 Billion INR | 98.948% |
| Medicamen Biotech Limited | 1.79 Billion INR | 39.356% |
| Medico Remedies Limited | 1.44 Billion INR | 24.967% |
| Megasoft Limited | 373.95 Million INR | -190.783% |
| Piramal Pharma Limited | 81.71 Billion INR | 98.669% |
| RPG Life Sciences Limited | 5.82 Billion INR | 81.318% |
| Sigachi Industries Limited | 3.98 Billion INR | 72.744% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -43.939% |
| Unichem Laboratories Limited | 16.57 Billion INR | 93.439% |
| Wanbury Limited | 5.75 Billion INR | 81.11% |
| Windlas Biotech Limited | 6.3 Billion INR | 82.766% |
| ZIM Laboratories Limited | 3.67 Billion INR | 70.405% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 99.428% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 90.555% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | 74.185% |
| Bal Pharma Limited | 3.39 Billion INR | 67.944% |
| Strides Pharma Science Limited | 40.51 Billion INR | 97.316% |
| Venus Remedies Limited | 5.91 Billion INR | 81.615% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 94.011% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 93.543% |
| Shilpa Medicare Limited | 11.51 Billion INR | 90.558% |
| Aarti Drugs Limited | 25.28 Billion INR | 95.7% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 94.868% |
| Suven Life Sciences Limited | 116.92 Million INR | -829.957% |
| Ind-Swift Limited | 5.02 Billion INR | 78.359% |
| Valiant Laboratories Limited | 1.82 Billion INR | 40.272% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 96.879% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 91.219% |
| Themis Medicare Limited | 3.81 Billion INR | 71.516% |
| Hikal Limited | 17.84 Billion INR | 93.907% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 98.975% |
| Sequent Scientific Limited | 13.69 Billion INR | 92.061% |
| Novartis India Limited | 3.35 Billion INR | 67.547% |
| Wockhardt Limited | 27.89 Billion INR | 96.101% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 98.378% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -171.608% |
| Neuland Laboratories Limited | 15.58 Billion INR | 93.023% |
| Morepen Laboratories Limited | 17.01 Billion INR | 93.611% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | 29.561% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | 70.499% |